Mycozal (Fluconazole)

Fluconazole inhibits the fungal enzyme 14α‑demethylase, a cytochrome P450 isoform that converts lanosterol to ergosterol, an essential component of the fungal cell membrane. By blocking this step, ergosterol synthesis is reduced, leading to defective membrane formation, increased permeability, and ultimately inhibition of fungal growth or cell death. Its selective affinity for the fungal enzyme provides antifungal activity with limited impact on human cells.

The dosage of Mycozal is determined by the prescribing clinician based on the infection being treated, the patient’s age, weight, renal and hepatic function, and any concomitant medications. Fluconazole dosing regimens vary widely, ranging from a single oral dose for uncomplicated candidiasis to daily doses for several weeks in systemic infections. Patients should follow the exact instructions provided by their healthcare professional.

Fluconazole is classified as a pregnancy‑category drug where safety depends on the dose and duration of therapy. Short courses for uncomplicated candidiasis are sometimes considered acceptable, while higher or prolonged doses may pose risks to the fetus. Breastfeeding mothers should discuss potential exposure with their physician, as fluconazole can be excreted in breast milk. The prescriber will weigh benefits against possible risks before recommending use.

To request Mycozal, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials to verify eligibility. After verification, the sales team provides pricing, availability, shipping details—including any temperature‑controlled handling if needed—and assists with import documentation.

Fluconazole, the active ingredient in Mycozal, belongs to the azole class and is distinguished by its oral bioavailability, relatively long half‑life, and activity against many Candida species and Cryptococcus. Compared with polyenes such as amphotericin B, fluconazole is less nephrotoxic and can be administered orally, but it has a narrower spectrum against molds. Clinicians select Mycozal when the infecting organism is known to be fluconazole‑susceptible and when oral therapy is preferred.

Mycozal should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original packaging to protect them from moisture and light, and store them out of reach of children. Do not refrigerate or freeze the product, as temperature extremes may affect tablet integrity.

Mycozal is taken orally, usually with a glass of water. The tablet can be swallowed whole and does not require food for absorption, although taking it with food may reduce gastrointestinal upset in some patients. The exact frequency and duration are prescribed by the treating physician based on the infection type and severity.

The most serious adverse reactions to fluconazole include hepatotoxicity, which may present as elevated liver enzymes or, rarely, severe liver injury; severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis; and cardiac effects like QT‑interval prolongation that can lead to arrhythmias. Patients should be monitored for signs of liver dysfunction, skin rash, or cardiac symptoms, and therapy should be discontinued if serious events occur.

Mycozal is contraindicated in individuals with a known hypersensitivity to fluconazole or other azole antifungals. Caution is also advised for patients with significant liver disease, uncontrolled cardiac arrhythmias, or those taking medications that strongly interact with fluconazole’s metabolic pathway. Pregnant women requiring high‑dose or prolonged therapy should avoid use unless the benefits clearly outweigh the risks.